menu
    • menu
    [{"orgOrder":0,"company":"Terumo","sponsor":"Terumo","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Nitrate","moa":"Carbonic anhydrase I (CA-I)","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Terumo","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Terumo \/ Terumo","highestDevelopmentStatusID":"1","companyTruncated":"Terumo \/ Terumo"},{"orgOrder":0,"company":"Terumo","sponsor":"Orchestra Biomed","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Collaboration","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Terumo","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Implant","sponsorNew":"Terumo \/ Terumo","highestDevelopmentStatusID":"4","companyTruncated":"Terumo \/ Terumo"},{"orgOrder":0,"company":"Terumo","sponsor":"Terumo","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"FRANCE","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Cangrelor","moa":"Purinergic receptor P2Y12","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Terumo","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Terumo \/ Terumo","highestDevelopmentStatusID":"11","companyTruncated":"Terumo \/ Terumo"}]

    Find Clinical Drug Pipeline Developments & Deals by Terumo

    Menu

    Terumo

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Terumo

                            Japan arrow
                            AAPS
                            Not Confirmed

                            Terumo

                            Japan arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sirolimus

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Undisclosed

                            Recipient : Orchestra Biomed

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Orchestra BioMed Announces Strategic Collaboration, Closing of $110 Million Private Equity Financing and Plans...

                            Details : Under the terms of their collaboration agreement, Orchestra BioMed and Terumo plan to execute a global clinical program Virtue SAB (sirolimus), in an effort to gain regulatory approval for commercial sale of Virtue SAB in multiple markets and indications...

                            Product Name : Virtue SAB

                            Product Type : Antibiotic

                            Upfront Cash : $30.0 million

                            July 05, 2022

                            Lead Product(s) : Sirolimus

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Undisclosed

                            Recipient : Orchestra Biomed

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Terumo

                            Japan arrow
                            AAPS
                            Not Confirmed

                            Terumo

                            Japan arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nitrate

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Undisclosed

                            Recipient : Inha University

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Effect of Ultimaster Stents Treated to the Most Dilated Coronary Vessels

                            Details : Nitrate is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Coronary Artery Disease.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            June 18, 2021

                            Lead Product(s) : Nitrate

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Undisclosed

                            Recipient : Inha University

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Terumo

                            Japan arrow
                            AAPS
                            Not Confirmed

                            Terumo

                            Japan arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cangrelor

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase IV

                            Recipient : University Hospital, Caen

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Evaluation of Myocardial Reperfusion After Primary PCI in Patients With High Platelet Reactivity Treated by Ca...

                            Details : Cangrelor is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of ST Elevation Myocardial Infarction.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            June 16, 2021

                            Lead Product(s) : Cangrelor

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase IV

                            Recipient : University Hospital, Caen

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth